Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.7 (
plasmin
)
9,023
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nicotine, a primary component of tobacco, is one of the most abused drugs worldwide. Approximately four million people die each year because of diseases associated with tobacco smoking. Mesolimbic dopaminergic neurons mediate the rewarding effects of abused drugs, including nicotine. Here we show that the tissue plasminogen activator (tPA)-
plasmin
system regulates nicotine-induced reward and dopamine release by activating protease activated receptor-1 (PAR1). In vivo microdialysis revealed that microinjection of either tPA or
plasmin
into the nucleus accumbens (NAc) significantly potentiated whereas plasminogen activator inhibitor-1 reduced the nicotine-induced dopamine release in the NAc in a dose-dependent manner. Nicotine-induced dopamine release was markedly diminished in tPA-deficient (tPA-/-) mice, and the defect of dopamine release in tPA-/- mice was restored by microinjection of either exogenous tPA or
plasmin
into the NAc. Nicotine increased tPA protein levels and promoted the release of tPA into the extracellular space in the NAc. Immunohistochemistry revealed that PAR1 immunoreactivity was localized to the nerve terminals positive for
tyrosine hydroxylase
in the NAc. Furthermore, we demonstrated that
plasmin
activated PAR1 and that nicotine-induced place preference and dopamine release were diminished in PAR1-deficient (PAR1-/-) mice. Targeting the tPA-
plasmin
-PAR1 system would provide new therapeutic approaches to the treatment of nicotine dependence.
...
PMID:The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. 1712 62
Nicotine, a primary component of tobacco, is one of the most abused drugs worldwide. Approximately four million people die a year because of diseases associated with tobacco smoking. Nicotine rapidly reaches the brain through smoking and this leads to nicotine dependence. Drugs of abuse including nicotine acutely modulate the activity of mesolimbic dopaminergic neurons, projecting from the ventral tegmental area of the midbrain to the nucleus accumbens (NAc). Recently, it has been proposed that activity-dependent synaptic plasticity and remodeling of the mesolimbic dopaminergic system play a crucial role in the development of drug dependence. Tissue plasminogen activator (tPA) is a serine protease that catalyzes the conversion of plasminogen to
plasmin
. In our previous study, we have demonstrated that the tPA-
plasmin
system participates in the rewarding effect of morphine and methamphetamine. Here we show that the tPA-
plasmin
system regulates nicotine-induced reward and dopamine release. In vivo microdialysis revealed that microinjection of either tPA or
plasmin
into the NAc significantly potentiated whereas plasminogen activator inhibitor-1 reduced the nicotine-induced dopamine release in the NAc in a dose-dependent manner. Nicotine-induced dopamine release was markedly diminished in tPA-deficient (tPA-/-) mice, and the defect of dopamine release in tPA-/- mice was restored by microinjection of either exogenous tPA or
plasmin
into the NAc. Nicotine increased tPA protein levels and promoted the release of tPA into the extracellular space in the NAc. Immunohistochemistry revealed that protease activated receptor-1 (PAR1)-immunoreactivity was localized to the nerve terminals positive for
tyrosine hydroxylase
in the NAc. Furthermore, we demonstrated that
plasmin
activated PAR1 and that nicotine-induced place preference and dopamine release were diminished in PAR1-deficient (PAR1-/-) mice. Our findings suggest that targeting the tPA-
plasmin
-PAR1 system would provide new therapeutic approaches to the treatment of nicotine dependence.
...
PMID:[Role of tissue plasminogen activator in the rewarding effect of nicotine]. 1864 40